Skip to content

Evaluation of Acute Stent Recoil in Large Vessels Treated with Sirolimus-eluting Stent

Optical Coherence Tomography Assessment of Acute Stent Recoil in Large Vessels Treated with Ultrathin Strut Biodegradable Polymer-coated Sirolimus-eluting Stent

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/055984
Enrollment
40
Registered
2023-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I209- Angina pectoris, unspecified

Interventions

Intervention1: NIL: NIL

Sponsors

Dr Atul D Abhyankar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years 2. Patient with symptomatic coronary artery disease 3. Patients with large vessels, who require treatment with the Supraflex Cruz stent with diameter >3.0 mm 4. The target lesions must be primary and in situ coronary lesions, and in the case of multiple target lesions, they must be located in different epicardial vessels. 5. Able to understand and sign the written informed consent form

Exclusion criteria

Exclusion criteria: 1. Contraindication to antiplatelet therapy or a history of hypersensitivity to sirolimus or structurally related compounds 2. Patient with any medical condition that would make him/her inappropriate for treatment with the Supraflex Cruz stent as per the current IFU or in the opinion of the Investigator 3. No suitable anatomy for OCT scan in the opinion of investigator 4. Internal mammary artery (IMA) due to a stent thrombosis 5. Heavily calcified lesion and/or calcified lesion which cannot be successfully pre-dilated 6. Previously implanted stent in target lesion(s) 7. Lesions in coronary artery bypass grafts 8. Known serum creatinine level >2.5mg/dl or presence or history of renal failure 9. Cardiogenic shock 10. Cerebrovascular accident or transient ischemic attack in the last 6 months. 11. Left ventricular ejection fraction (LVEF) <30% at the most recent evaluation

Design outcomes

Secondary

MeasureTime frame
Segment level analysis (cross-sectional areas of stent, lumen, prolapse & isolated intraluminal defect using OCT examinationsTimepoint: After Index Procedure

Primary

MeasureTime frame
Acute stent recoil, defined as a decrease in the mean stent area (MSA, mm2) from baseline to approximately 30 minutes after stent implantation using OCT examinations.Timepoint: After Index Procedure

Countries

India

Contacts

Public ContactDr Atul D Abhyankar

Shree B.D. Mehta Mahavir Heart Institute

atulda.abhyankar@gmail.com9824145738

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026